Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families

Breast Cancer Research and Treatment

Volumn 108, Issue 3, 2008, Pages 399-408

  Arcand, Suzanna L ^a   Maugard, Christine M ^b,c   Ghadirian, Parviz ^b   Robidoux, André ^b   Perret, Chantal ^d   Zhang, Phil ^e   Fafard, Eve ^b   Mes Masson, Anne Marie ^c,d   Foulkes, William D ^a,f,g   Provencher, Diane ^a,c,d   Narod, Steven A ^e   Tonin, Patricia N ^a,f,h  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer; Founder effects; French Canadian; TP53

Indexed keywords

ARGININE; BRCA1 PROTEIN; BRCA2 PROTEIN; GLUTAMINE; HISTIDINE; PROTEIN P53;

ARTICLE; BREAST CANCER; CANADA; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENETIC ANALYSIS; HUMAN; INTRON; NUCLEOTIDE SEQUENCE; OVARY CANCER; PEDIGREE ANALYSIS; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION;

EID: 41149160304     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9608-6     Document Type: Article

References (42)

1. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63(5):1341-1351
2. Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD et al (2004) Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 112(3):411-419
3. Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN (2006) Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet 70(4):320-329
4. Antoniou AC, Durocher F, Smith P, Simard J, Easton DF (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8(1):R3
5. Simard J, Dumont M, Moisan AM, Gaborieau V, Vezina H, Durocher F, Chiquette J, Plante M, Avard D, Bessette P et al (2007) Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multi-step testing approach in French-Canadian high-risk breast and ovarian cancer families. J Med Genet 44(2):107-121
6. Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson AM et al (2001) Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered 52(2):116-120
7. Scriver CR (2001) Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2:69-101
8. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA (2005) Population history and its impact on medical genetics in Quebec. Clin Genet 68(4):287-301
9. Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, Chiquette J, Plante M, Laframboise R, Lepine J et al (2005) Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 117(2-3):119-132
10. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadiran P, Provencher D, Tonin PN (2006) Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 7(1):23
11. Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898-5905
12. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358-5362
13. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54(5):1298-1304
14. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, Li FP, Friend SH (1995) Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56(3):608-615
15. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57(15):3245-3252
16. Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM (2002) Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 39(12):941-944
17. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20):6643-6650
18. Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79(6):1213-1220
19. Garber JE, Burke EM, Lavally BL, Billett AL, Sallan SE, Scott RM, Kupsky W, Li FP (1990) Choroid plexus tumors in the breast cancer-sarcoma syndrome. Cancer 66(12):2658-2660
20. Hartley AL, Birch JM, Tricker K, Wallace SA, Kelsey AM, Harris M, Jones PH (1993) Wilms' tumor in the Li-Fraumeni cancer family syndrome. Cancer Genet Cytogenet 67(2):133-135
21. Eeles RA, Bartkova J, Lane DP, Bartek J (1993) The role of TP53 in breast cancer development. Cancer Surv 18:57-75
22. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101-124
23. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233-1238
24. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP (1991) Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51(22):6094-6097
25. Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ (1991) Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 63(2):181-184
26. Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52(11):3234-3236
27. Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, Anderson K, Evans AM, DeMars R, Love R et al (1992) No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 7(5):1043-1046
28. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT (1994) Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 9(1):97-102
29. Sun XF, Johannsson O, Hakansson S, Sellberg G, Nordenskjold B, Olsson H, Borg A (1996) A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13(2):407-411
30. Rapakko K, Allinen M, Syrjakoski K, Vahteristo P, Huusko P, Vahakangas K, Eerola H, Kainu T, Kallioniemi OP, Nevanlinna H et al (2001) Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 84(1):116-119
31. Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL (2003) Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 40(4):e34
32. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama 295(12):1379-1388
33. Ye S, Dhillon S, Ke X, Collins AR, Day IN (2001) An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29(17):E88-8
34. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, Shields PG, Modali R, Turner BC (2000) Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 60(4):1062-1069
35. Balz V, Prisack HB, Bier H, Bojar H (2002) Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genet Cytogenet 138(2):120-127
36. Bendig I, Mohr N, Kramer F, Weber BH (2004) Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin. Cancer Genet Cytogenet 154(1):22-26
37. Lalloo F, Varley J, Moran A, Ellis D, O'Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143-1150
38. Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van TVLJ Menko FH (2006) Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. Fam Cancer 5(2):169-174
39. Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP (1999) p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene 18(27):3970-3978
40. Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lepine J, Lesperance B et al (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230
41. Tischkowitz M, Xia B, Sabbghian N, Reis-Filho JS, Hamel N, Li G, van Beers EK, li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD (2007) Analysis of PALB2/FANCN-associated breast cancer families. PNAS 104(16):6788-6793
42. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165-167